GammaCan International Inc., Appoints Dr. Pearl Grimes, Founder & Director of the Vitiligo and Pigmentation Institute of Souther

GammaCan International, Inc. (OTC BB: GCAN) today
announced the appointment of Dr. Pearl Grimes, Founder & Director of
the Vitiligo and Pigmentation Institute of Southern California and
Clinical Professor of Dermatology at the University of California, Los
Angeles, to the Company's Scientific Advisory Board.
   Dr. Grimes is nationally and internationally recognized for her
work on pigmentary disorders. She lectures worldwide on pigmentary
disorders including vitiligo, Melasma, and post-inflammatory
hyperpigmentation to name a few.
   "We view the appointment of Dr Grimes to our SAB as critical to
GammaCan's mission reaching out to the large population affected by
Vitiligo whom Dr. Grimes has made her life's mission to help.
Moreover, we see substantial synergies in our mutual interest
involving the study of Vitiligo and thus in bringing VitiGam into the
clinic and later on to the market," stated Patrick Schnegelsberg, CEO.
   Dr. Grimes is the past Assistant Editor of the Journal of the
American Academy of Dermatology, and has served on the Editorial Board
of the Journal of Clinical Dermatology, Practical Dermatology, and
Skin & Allergy News. Dr. Grimes is presently a contributing editor to
Cosmetic Dermatology. As founder of The Vitiligo and Pigmentation
Institute of Southern California and its ongoing research program, Dr.
Grimes' mission is to provide cutting edge therapies to patients
suffering from vitiligo and other pigmentary disorders. She has
authored over 100 publications and abstracts and is a member of: The
American Academy of Dermatology, the American Society of
Dermatological Surgery, the American Dermatological Association,
Society of Investigative Dermatology, Dermatology Foundation, and
International Pigment Cell Society. Dr. Grimes is a graduate of
Washington University in St. Louis, Missouri and completed her
dermatology residency at Howard University Hospital in Washington,
D.C.

   About VitiGam:
   VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.

   About GammaCan
   GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
   For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at [phone]
or toll free 1-866-308-0396 (from North America).

   Safe Harbor Statement:
   Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.